Urszula A.
- Country
- Poland
- Department
- Centrum Zdrowia MDM
Research Overview
- Efficacy and Safety Evaluation of Pembrolizumab in Advanced Progressive Adrenocortical Carcinoma: A Multicenter Phase 2 Open-Label Study
- A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants with Classic Congenital Adrenal Hyperplasia
- Evaluation of Tildacerfont in Reducing Supraphysiologic Glucocorticoid Use in Adults with Classic Congenital Adrenal Hyperplasia: A Randomized, Double-Blind, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 21 of 57 partner sites.
Specializations
Endocrine Disorders
The investigator specializes in the treatment of Classic Congenital Adrenal Hyperplasia (CAH), focusing on innovative therapeutic approaches for managing hormone levels and optimizing treatment outcomes.
- Hormone regulation in CAH patients
- Blood hormone level management
- Glucocorticoid therapy optimization
Their research extends to evaluating novel therapeutic agents for improving hormone control in adult CAH patients.
Oncology
The investigator conducts research in rare endocrine cancers, with particular emphasis on adrenocortical carcinoma and its advanced treatment modalities.
- Advanced adrenocortical cancer therapy
- Progressive disease management
- Immunotherapy applications
Their work encompasses evaluating innovative therapeutic approaches for patients with advanced endocrine malignancies.
Therapeutic Innovation
The investigator focuses on developing and evaluating novel treatment strategies for endocrine conditions, particularly in hormone-dependent disorders.
- Long-term treatment evaluation
- Medication dose optimization
- Treatment efficacy assessment
Their research aims to advance therapeutic options for patients with complex endocrine disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.